Annual Report - Glenmark

More documents

Recommendations

Info

Research-focused 6 In the post-GATT era, the growing importance of research is reflected at two levels. To begin with, there is the need to create new revenue inflows through innovation and new product development in the generics segment. Furthermore, this should be complemented by developing commercially-viable, proprietary products so that organisations can enjoy their competitive benefits for a longer period of time. Responding proactively to these imperatives, Glenmark had drawn out a dynamic three-pronged R&D initiative that covers the following: New chemical entity [NCE] research: The Company is focused on selecting targets with a strong possibility of success and having a high commercial potential. It has targeted development of new molecules in the asthma, diabetes and obesity therapeutic segments. This approach has yielded exciting results with one of the drug candidates successfully completing Phase I of clinical trials and a few others expected to move into the clinical trial stage in FY 2006. enhancing the value of its existing formulation therapies by developing patentable drug delivery systems that would help create strong differentiated products. These research teams are housed across its two research facilities at Sinnar and Mahape. This work has led to a patented controlled-release technology through which Glenmark is planning to commercialise several products in the future. Strong process chemistry research: The third initiative of reverse engineering bulk drugs is a recent, but significant contributor to the R&D vision. The Company filed patents on thirty nine processes in FY 2005. In addition, the process research teams also contribute to the NCE activity by developing and scaling up APIs for novel drugs discovered by Glenmark. These R&D initiatives have already commenced in generating returns and are expected to continue to translate into a more valuable product basket, stronger revenues, enhanced margins and higher profits. Formulations and new drug delivery systems [NDDS]: In addition to creating new formulations, the Company is also
A committed research and development focus has emerged as a differentiator for success in the pharmaceutical industry today Annual Report 2004-2005 7
Page 1 and 2: Glenmark Pharmaceuticals Limited An
Page 3: Consolidated Financial Highlights Y
Page 6 and 7: Global. Research-focused. Integrate
Page 8 and 9: Global accounts for half the global
Page 12 and 13: Integrated 8 Glenmark's business st
Page 14 and 15: Highlights, 2004-05 Consolidated re
Page 16 and 17: Interview with MD & CEO 12 Glenn Sa
Page 18 and 19: Our lead compound for Asthma and CO
Page 20 and 21: Business Divisional Analysis 16 Ind
Page 22 and 23: Domestic Formulations Performance H
Page 24 and 25: 20 accounted for almost 50 percent
Page 26 and 27: Active Pharmaceutical Ingredients 2
Page 28 and 29: Therapeutic segment contribution in
Page 30 and 31: International Formulations Performa
Page 32 and 33: 28 percent evinced a growth spurt i
Page 34 and 35: Research and Development 30 JANUARY
Page 36 and 37: 32 compounds are licensed to global
Page 38 and 39: Diabetes/Obesity Incidence Globally
Page 40 and 41: Global Management Team Name Glenn S
Page 42 and 43: 38 Revenues Glenmark's turnover for
Page 44 and 45: 40 Secured Loans Secured loans incr
Page 46 and 47: existing employees to keep them in
Page 48 and 49: 44 who are geared to respond to and
Page 50 and 51: Profit & loss Account (Rs. in ‘00
Page 52 and 53: PAT Margin Research and development
Page 54 and 55: Directors’ Report Your Directors
Page 56 and 57: 52 of the Company. On exercising th
Page 58 and 59: Annexure to the Directors’ Report
Page 60 and 61:
v. The products launched and sold i
Page 62 and 63:
Disclosure pursuant to the provisio
Page 64 and 65:
Report on Corporate Governance Purs
Page 66 and 67:
B. Given below are the details of r
Page 68 and 69:
He is also a Director of following
Page 70 and 71:
Further resolutions with requisite
Page 72 and 73:
(All figures in Indian Rupees) Mont
Page 74 and 75:
) Risk as to fraudulent encashment
Page 76 and 77:
ANNEXURE TO AUDITORS’ REPORT Refe
Page 78 and 79:
Balance Sheet Rs. In (’000s) As a
Page 80 and 81:
Cash Flow Statement Rs. In (’000s
Page 82 and 83:
Schedules forming part of the Balan
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Schedules to the Profit & Loss Acco
Page 92 and 93:
Schedules forming part of the Finan
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
100 SECTION 212 STATEMENT PURSUANT
Page 106 and 107:
Consolidated Balance Sheet Rs. In (
Page 108 and 109:
Consolidated Cash Flow Statement Rs
Page 110 and 111:
Schedules forming part of the Conso
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
114 Notes to the Consolidated Accou
Page 120 and 121:
Notes to the Consolidated Accounts
Page 122 and 123:
118 Notes to the Consolidated Accou
Page 124:
14 13 12 43 19 71 49 10 5 20 62 3 3
show all

Annual Report - Glenmark

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?